Compare DXPE & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DXPE | SLS |
|---|---|---|
| Founded | 1908 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.7B |
| IPO Year | 1998 | 2007 |
| Metric | DXPE | SLS |
|---|---|---|
| Price | $184.14 | $11.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $154.00 | $10.00 |
| AVG Volume (30 Days) | 74.3K | ★ 7.2M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 27.25 | ★ 50.00 |
| EPS | ★ 2.98 | N/A |
| Revenue | ★ $1,247,043,000.00 | N/A |
| Revenue This Year | $9.31 | N/A |
| Revenue Next Year | $7.85 | $110.98 |
| P/E Ratio | $61.62 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $84.04 | $1.39 |
| 52 Week High | $208.00 | $15.88 |
| Indicator | DXPE | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 49.75 | 42.35 |
| Support Level | $180.88 | $10.85 |
| Resistance Level | $183.91 | $15.77 |
| Average True Range (ATR) | 5.22 | 1.05 |
| MACD | -1.28 | -0.36 |
| Stochastic Oscillator | 37.76 | 18.55 |
DXP Enterprises Inc is engaged in the business of distributing maintenance, repair and operating (MRO) products, equipment and service to customers in various end markets, including general industrial, energy, food & beverage, chemical, transportation, water and wastewater. The company operates through three business segments: Service Centers, Innovative Pumping Solutions and Supply Chain Services. The majority of revenue is derived from the Service Centers segment, which provides a wide range of MRO products in the rotating equipment, bearing, power transmission, hose, fluid power, metal working, fastener, industrial supply, safety products and safety services categories. Geographically, it generates the maximum revenue from the United States.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.